2023 - New Diagnostics and Emerging Biomarkers for Alzheimer’s Disease

Research into Alzheimer’s disease has reached an extraordinary inflection point. Decades of research have yielded tractable therapeutic targets, resulting in drugs that have earned accelerated US Food and Drug Administration (FDA) approvals. Biomarker research has been essential in driving therapeutic advances.
Over the last decade, an array of biomarkers to identify, classify, stage and monitor Alzheimer’s disease patients have been discovered and studied resulting in clinically useful, cost-effective and less invasive diagnostic methods to expedite clinical trials and identify Alzheimer’s disease faster and more accurately. With the establishment of the ATN research framework for biomarkers of Amyloid, Phospho-Tau and Neurodegeneration in 2018, a paradigm for understanding the relationship between various biomarkers and disease biology/pathology has emerged, enabling advancements in Alzheimer’s disease biomarker and therapeutic research. This has led to new blood-based biomarker solutions for drug development trials and clinic use.
This webinar will review the current landscape of Alzheimer’s disease biomarkers and diagnostics. The featured speakers will discuss blood-based biomarkers in light of Labcorp’s newly launched ATN panel that can provide insight into patient risks for Alzheimer’s disease and other neurodegenerative conditions. The webinar will also highlight emerging biomarkers, such as GFAP and YKL40 that may supplement the core ATN panel to further enhance the understanding of, and the ability to identify and differentiate neurodegenerative diseases.